Skip to main content
. Author manuscript; available in PMC: 2024 Apr 1.
Published in final edited form as: Gynecol Oncol. 2023 Feb 17;171:49–58. doi: 10.1016/j.ygyno.2023.02.004

Table 1.

Affinity measurement of chimeric, humanized and humanized affinity-matured EGFL6 antibodies

Ab Name Capture Analyte ka (1/Ms) kd (1/s) KD (nM) Chi2 (RU2)
Chimeric Chimeric Human EGFL6 2.15E+04 1.27E−03 59.20 3.74E+00
CBM VH1-CBM + VL1-CBM Human EGFL6 5.30E+05 2.10E−03 3.97 3.39E+00
#9 VH2+VL1 Human EGFL6 2.57E+05 5.46E−05 2.13 6.38E−01
#10 VH2+VL2 Human EGFL6 2.92E+05 6.15E−04 2.11 1.26E+00
#11 VH3+VL2 Human EGFL6 3.11E+05 5.29E−04 1.70 7.79E−01
#12 VH4+VL2 Human EGFL6 1.93E+05 5.15E−04 2.67 7.34E−01
#13 VH5+VL3 Human EGFL6 3.74E+05 1.11E−04 0.30 4.84E−01
#15 VH1+VL2 Human EGFL6 4.04E+05 1.30E−04 0.32 1.44E−01
#16 VH1+VL1 Human EGFL6 3.83E+05 5.66E−05 0.15 2.21E−01